diclofenac has been researched along with roflumilast in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balliano, TL; Barbosa, G; Carvalho, VF; da Silva, BA; de Souza, ET; Lima, LM; Martins, IRR; Martins, MA; Medeiros, MM; Moraes Junior, MO; Nunes, IKDC; Silva, PMR; Silva, SWD | 1 |
| Colbatzky, F; Göggel, R; Nickolaus, P; Peter, D | 1 |
2 other study(ies) available for diclofenac and roflumilast
| Article | Year |
|---|---|
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice | 2020 |
Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats.
Topics: Acute Lung Injury; Aminopyridines; Animals; Benzamides; Bronchoalveolar Lavage Fluid; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cyclopropanes; Diclofenac; Disease Models, Animal; Humans; Inflammation; Lipopolysaccharides; Male; Neutrophil Infiltration; Phosphodiesterase 4 Inhibitors; Pyrazoles; Rats; Rats, Wistar | 2011 |